Findings pave the way to potentially use PLX-R18 to support hematological recovery following radiotherapy or …
Aspertec 325 mg and Aspertec 81 mg (referred to together as Aspertec), has completed its previously announced merger with Dipexium Pharmaceuticals, Inc. (Dipexium), effective as of April 19, 2017. The combined companywhich changed …
PLx stockholders will receive newly issued shares of common stock of Dipexium in connection with the merger contemplated by the merger agreement. Dipexium will issue approximately 36 million new shares of its common stock …
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced the entry into a definitive exchange ... approximately 23.8 million …
Investors in Protalix BioTherapeutics, Inc. PLX need to pay close attention to the stock based on moves in the options market lately. That is because the May 19 th 2017 $1.00 Call had some of the highest implied volatility of all equity …